-
Biocytogen and FineImmune Partner on Innovative Cell Therapy Drug Development
•
China-based Contract Research Organization (CRO) Biocytogen (Beijing) Co., Ltd has entered into a collaboration with compatriot firm FineImmune. Biocytogen will utilize its self-developed TCR-like antibody technology platform to screen fully human antibody sequences against specific targets and jointly develop innovative cell therapy drugs targeting intracellular tumor-related antigens, combining FineImmune’s unique…
-
CMS’s Rxilient Medical Licenses Insulin Products from Hefei Tianmai Biotech
•
China Medical System Holdings (CMS; HKG: 0867) announced that its subsidiary Rxilient Medical Pte. Ltd has entered into a licensing, collaboration, and supply agreement with Hefei Tianmai Biotechnology Co. Ltd regarding its second-generation insulin and third-generation insulin analogue insulin glargine. Under the agreement, CMS will hold exclusive licensing rights to…
-
Kelun Pharmaceutical Receives USD 35 Million from Merck Sharp & Dohme Corp.
•
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) announced that it has received a USD 35 million payment from US-based Merck Sharp & Dohme Corp. (MSD), in accordance with the licensing agreement signed in July this year. Under the agreement, MSD has obtained global development, manufacturing, and commercial rights to…
-
Hainan Yuekang’s YK-029A Biosimilar Set for BTD in EGFR ex20ins NSCLC
•
The Center for Drug Evaluation (CDE) website indicates that China-based Hainan Yuekang Biological Medicine Co., Ltd’s YK-029A, a biosimilar of Tagrisso (osimertinib), is set to gain Breakthrough Therapy Designation (BTD) status for use in advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (EGFR ex20ins). YK-029A, an…
-
Walvax Biotech Enrolls First Subject in Phase III HPV Vaccine Study
•
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) announced the first subject enrollment for a Phase III clinical study assessing the immunogenicity of its in-house developed nine-valent human papillomavirus (HPV) vaccine compared with Merck Sharp & Dohme’s (MSD) Gardasil 9. The vaccine is designed for the prevention of cervical cancer, vulvar…
-
Sinocelltech’s Ripertamab Officially Launched in China for DLBCL Treatment
•
China-based Sinocelltech Group Ltd (SHA: 688520) announced the first deliveries and prescriptions of its ripertamab (SCT400), marking the official national launch of the drug in China. The innovative CD20 monoclonal antibody (mAb) is described as similar in efficacy and safety to rituximab and was approved on August 31 for treating…
-
Innovent’s Tyvyt Shows PFS Benefit in EGFR-Mutant NSCLC at ESMO
•
China-based Innovent Biologics, Inc. (HKG: 1801) presented results of the ORIENT-31 study for its PD-1 inhibitor Tyvyt (sintilimab) at the 2022 European Society for Medical Oncology (ESMO) annual meeting. The study evaluated Tyvyt, with or without Bevagen (bevacizumab), a biosimilar version of Avastin, in combination with chemotherapy for EGFR-mutant non-squamous…
-
Luye Pharma’s CD25 Monoclonal Antibody BA1106 Gains NMPA Approval for Clinical Trials
•
China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s in-house developed CD25 monoclonal antibody (mAb) BA1106 has received clinical trial approval from the National Medical Products Administration (NMPA). This makes BA1106 the first CD25-targeted drug to enter clinical trials in China for the treatment…
